SecBot SecBot

VCRE

Vicore Pharma Holding AB
Nasdaq· CIK 0002124403
$9.40 +0.02 (+0.21%)
Oct 26 4:00 PM ET · prev $9.38
Market cap
$2.9B
Mid cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
🔒 Subscribers only
Since first trade
−42.2%
from $16.25 · Jul 6
30 days
−2.0%
from $9.59
Range since listing
$8.66–16.25
−42% from high · low Oct 7
Avg volume 20D
28.9K
Oct 22 spike 103.3K
Short interest
🔒 Subscribers only
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BULLISH Vicore Pharma announced that the Phase 2b ASPIRE trial of buloxibutid in IPF passed a pre-planned futility…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better.

  • TrendDOWNTREND

    9% below its 50-day average.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy5Buy7Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 9, 2026Jefferies
INITIATE
INITIATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 6, 2026
Trading halt
Halt Resumed: VCRE — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-06T17:53:31.000Z | Resumed 2026-07-06T18:03:31.000Z
Jul 6, 2026
Trading halt
Trading Halt: VCRE — LUDP (Volatility Trading Pause)
Vicore Pharma Hldg ADS | Market: NASDAQ | Code: LUDP — Volatility Trading Pause

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$781.5K
Next Q———$781.5K
Current FY———$7.7M
Next FY———$44.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 6, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Vicore Pharma announced that the Phase 2b ASPIRE trial of buloxibutid in IPF passed a pre-planned futility analysis…
6-K — Impact 5/10
Oct 13, 2026 SEC
HBM Healthcare Investments (Cayman) Ltd. filed a Schedule 13G disclosing a passive 8% beneficial ownership stake in…
SC 13G — Impact 3/10
Sep 30, 2026 SEC
Vicore Pharma issued 118,916 new shares via warrant exercises under Board LTIP 2023/2024 and Board RSU 2025 incentive…
6-K — Impact 2/10
Jul 6, 2026 Trading halt
Halt Resumed: VCRE — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-06T17:53:31.000Z | Resumed 2026-07-06T18:03:31.000Z

SecBot reports

4 filings · 1 bullish · 0 bearish · 3 neutral
All VCRE filing & press-release reports (4)